Semaglutide 0.25 mg to 2.4 mg pre-filled injection pens

Yes, but only as a separate product. Semaglutide is authorised in one product line for blood sugar control and cardiovascular risk in adults with type 2 diabetes, and in another for chronic weight management in adults with obesity or who are overweight with a weight-related condition. They use different pens and different dose steps, and prescribing the diabetes product for weight alone is off-label. We dispense against what your prescriber writes and cannot advise you on which is appropriate for you — that conversation belongs with them.

Blood sugar starts to change within the first weeks, but the 0.25 mg starting dose is deliberately a run-in dose, chosen so your stomach can adjust, not to control glucose. Most people move to 0.5 mg after 4 weeks and may go higher after that. The label expects the full effect of a given dose to take several weeks to show, so HbA1c is usually rechecked after about three months. Do not increase your own dose because progress feels slow — dose steps belong to your prescriber.

If it is within 5 days of the day you should have injected, take it as soon as you can and then go back to your usual weekly day. If more than 5 days have gone by, skip that dose entirely and take the next one on your normal schedule. Do not double up. If you miss doses often, tell your prescriber — restarting after a long gap sometimes means going back to a lower dose, because tolerance to the stomach side effects fades when you stop.

Before first use, keep the pen in the fridge at 2 to 8 °C, and never freeze it — a frozen pen must be thrown away. Once you have used it, the pen can be kept for 56 days (8 weeks) either in the fridge or at room temperature below 30 °C, with the cap on and away from light and heat. Take the needle off after each injection. After 56 days, throw the pen away even if there is medicine left. If a pen has been left somewhere hot, or has frozen, do not use it — ask our pharmacist.

No. Semaglutide is a prescription-only medicine and we dispense it only against a valid prescription from your licensed prescriber. It carries a boxed warning about thyroid tumours, is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and interacts with insulin and sulfonylureas in ways that can cause dangerous low blood sugar. A licensed pharmacist reviews every order here. Semaglutide sold without a prescription, or compounded from unlicensed sources, is a route we will not touch.

We dispense semaglutide injection pens as 0.25 mg/1.5 mL (1 pen), 0.5 mg/1.5 mL (1 pen), 1 mg/3 mL (1 pen), 1.7 mg/3 mL (1 pen) and 2.4 mg/3 mL (1 pen). The current price for each pack is shown on this page and again in your cart before you pay, with no membership fee and no tiers. Stock may be branded or generic on any given day, depending on what is in supply; the active ingredient, the strength and the pack size are what the label says either way. What we dispense is set by your prescription rather than by what you select, so if the quantity on your prescription differs from the pack you picked, our pharmacist will contact you before anything is sent.

We dispense only where we are licensed to dispense, and the checkout tells you whether we can ship to your address before you pay. Semaglutide needs to stay refrigerated until first use, so it ships in insulated packaging with cooling, and delivery windows are shorter than for tablets. If a parcel arrives warm, arrives damaged, or has clearly been frozen, do not use the pen — contact us and our pharmacist will deal with it. Current timings and carriers are on our shipping page.

In rodent studies, semaglutide caused dose-related thyroid C-cell tumours, including medullary thyroid carcinoma, at exposures relevant to human doses. Whether the same happens in people is not known — the relevance of the rodent finding to humans has not been determined. Because of that uncertainty, semaglutide carries a boxed warning and is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2. The label asks you to report a neck lump, hoarseness, trouble swallowing or shortness of breath to your prescriber.